New review article coauthored by Dr Gerry Kenna published in the journal Clinical Pharmacology & Therapeutics:
Medicines can cause serious unwanted side effects in some patients. These include drug-induced liver injury (DILI), which is poorly predicted by the currently used safety test methods. Assays that focus on human-relevant mechanisms can provide more useful data. One important mechanism is inhibition of a liver cell membrane transport protein called the Bile Salt Export Pump (BSEP). This article reviews the evidence linking BSEP inhibition with DILI and describes methods to evaluate and interpret BSEP inhibition. It also recommends how these data can be used to aid the design and selection of safer medicines. The authors from Safer Medicines Trust, major pharmaceutical companies, universities and biotechnology companies were brought together by the International Transporter Consortium.
By Rebecca Ram This month marks World Liver Day (held every year on 19 Apr) to raise awareness about diseases of the second largest organ in the body. After the brain, the liver is the most complex organ and is vital to the efficient control of the gastrointestinal (digestive) system. Liver diseases account for approximately […]
New Approach Methodologies in COVID-19: systematic review into the neurological effects of SARS-CoV-2 infection presented at SOT (Society of Toxicology) Congress 2022By Rebecca Ram Launched nearly two years ago, the CIAO project (Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway Framework) involves the collaboration of scientific experts to identify the chemical and biological events involved in the body’s response to the SARS-CoV-2 virus. Expert working groups are established across a number of areas, for […]